Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.